Mink Therapeutics (INKT) Q4 2024 earnings summary

Executive summary

• Achieved significant progress in 2024, advancing off-the-shelf iNKT cell therapies for solid tumors, hard-to-treat cancers, and immune-driven diseases, with clinical, manufacturing, and leadership advancements including Dr. Robert Kadlec joining the board.

• Entered a strategic research collaboration with Autonomous Therapeutics to integrate encrypted RNA technology with iNKT cell therapies, targeting next-generation cancer treatments and metastatic tumors.

• Prioritized externally funded clinical trials and raised $5.8M in private financing to support pipeline advancement.

• Presented compelling clinical and preclinical data at major conferences, demonstrating enhanced immune activation and synergy with checkpoint inhibitors.

Financial highlights

• Ended 2024 with a cash balance of $4.6 million, down from $5.7 million at year-end 2023.

• Net loss for 2024 was $10.8 million ($2.86 per share), improved from $22.5 million ($6.54 per share) in 2023.

• Cash used in operations was $9.6 million for 2024, down from $15.8 million in 2023.

Outlook and guidance

• Plans to deliver additional clinical data from the gastric cancer trial and advance the GVHD study into patient dosing in 2025.

• IND filing for FAP CAR INKT and 215 programs targeted for 2025.

• Late-stage trials for AgenT-797 in ARDS are designed and planned for regulatory discussions.

• Positioned to scale efficiently and pursue new collaborations for value creation in 2025 and beyond.

• Cash runway projected through the end of 2025, with ongoing efforts to secure non-dilutive and partnership funding.